Skip to main content
HANALL BIOPHARMA CO.,LTD logo

HANALL BIOPHARMA CO.,LTD — Investor Relations & Filings

Ticker · 009420 ISIN · KR7009420001 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2024-01-24 Director's Dealing
Country KR South Korea
Listing KO 009420

About HANALL BIOPHARMA CO.,LTD

http://www.hanallbiopharma.com/

HanAll Biopharma is a global biopharmaceutical company focused on developing innovative, first-in-class therapies for patients with unmet medical needs. The company's research and development efforts are centered on immunology, ophthalmology, and immuno-oncology, with a specialization in antibody-based therapeutics. Its pipeline includes novel treatments for autoimmune diseases and dry eye disease. The company's mission is to pioneer cutting-edge medicines that address incurable and immune-associated conditions. Alongside its innovative pipeline, HanAll Biopharma also operates a portfolio of pharmaceutical products in therapeutic areas including endocrine, circulatory, and urologic diseases.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (specifically '장내매수' or on-market purchase) by a company executive (CEO Seungwon Jeong) of Hanall Biopharma. This is a standard regulatory filing for insider trading/director dealings.
2024-01-24 Korean
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the acquisition of shares by a company executive (CEO Seungwon Jeong) and includes a correction (정정신고) regarding the transaction price. This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) report, as it documents insider share transactions.
2024-01-24 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) filed by HanAll Biopharma. It details specific changes in share ownership by major shareholders and executives (specifically an executive named Jung Seung-won). This type of filing is a standard regulatory requirement for reporting changes in significant shareholdings or insider holdings. Given the focus on major shareholding thresholds and changes, it aligns best with the 'Major Shareholding Notification' category.
2024-01-24 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the National Pension Service's change in shareholding percentage in HanAll Biopharma. This falls under the category of Major Shareholding Notification.
2024-01-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by the National Pension Service regarding HanAll Biopharma. This is a standard regulatory filing in South Korea (DART system) used to disclose changes in significant shareholdings (major shareholding notification). It details the specific dates, transaction types (buy/sell), and share counts, which aligns with the definition of a Major Shareholding Notification.
2024-01-04 Korean
투자판단관련주요경영사항(자가면역질환 치료 항체신약 HL161의 일본 갑상선 안병증 임상 3상을 위한 시험계획서(CTN) 승인)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory filing from HanAll Biopharma submitted to the Korea Exchange (KRX) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It specifically announces the approval of a Clinical Trial Notification (CTN) for a Phase 3 clinical trial in Japan. Since this is a mandatory disclosure of a material corporate event (clinical trial approval) rather than a financial report, a dividend notice, or a management change, it falls under the 'Regulatory Filings' category as the most appropriate classification for miscellaneous material disclosures.
2023-12-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.